Katoro Gold (LON: KAT) has appointed Beaumont Cornish as nominated adviser and the share price recovered by two-thirds to 0.175p. Previous nominated adviser RFC Ambrian resigned, and a replacement needed to be found by 11 January or trading in the shares would have been suspended. The minerals explorer requires cash to fund its iron ore project in Namibia.
Subsea cable protection services provider Tekmar Group (LON: TGP) has won several significant contracts worth more than £8m. These will be delivered in the first half of 2023. The share price moved up 32.1% to 17.5p, which is the highest it has been since June.
Industry intelligence provider GlobalData (LON: DATA) says 2022 revenues are at the higher end of expectations. They increased from £189.3m to £242m, with a one-third increase in EBITDA to £86m. Net debt is £252m. Current year forecasts have been upgraded. There is 80% revenue visibility for 2023. There was a 12.7% jump in the share price to 1335p.
Zenova Group (LON: ZED) has received a US order for 7,500 units of the FX500 mini fire extinguisher. The share price rose 11.9% to 11.75p.
Supreme (LON: SUP) had a better than expected Christmas trading period. Vaping revenues continue to grow, while lighting revenues are recovering. The other products are trading steadily. The consumer products supplier is on course for market expectations of 2022-23 earnings of 9.6p a share. The share price is 11.3% ahead at 113p.
Biopesticides developer Eden Research (LON: EDEN) expects 2022 revenues to increase by 50% to £1.8m. New authorisations have boosted product sales. The loss will be slightly lower at around £2.8m. There is still cash of £2m, but this will reduce further this year. The share price improved by 9.4% to 4.65p.
A heavily discounted placing by Nanosynth (LON: NNN) has knocked 23.6% off the share price to 0.21p. The £400,000 was raised at 0.18p a share. This cash will provide additional working capital.
Model railways supplier Hornby (LON: HRN) says that its third quarter sales were ahead of the same period last year. Sales in the first nine months of the financial year are 6% ahead, but management is cautious about the future. Net debt has increased to £7.6m. The share price fell by 19% to 23.5p.
Braveheart Investment Group (LON: BRH) says sales of investee company Phasefocus were lower than expected due to the loss of a distributor. A £300,000 cash raising is planned to fund sales activity. Life sciences subsidiary Paraytec is undertaking a clinical study for rapid diagnostics tests in Sheffield. A lack of NHS staff has delayed the trial and the initial results have been delayed to February. The Braveheart Investment share price declined by 14.5% to 8.125p.
